Nicholas Galakatos, a veteran of biotech ventures, with more than two decades of industry and investment experience in the healthcare sector.

 He is a co-founder and Managing Director of Clarus Ventures since the firm’s inception in 2005.

Dr. Galakatos was a General Partner at MPM Capital, a healthcare venture capital firm.

From 1997 to 2000, he was Vice President of New Business at Millennium Pharmaceuticals (Takeda) and a member of the Management Team.

During that time Galakatos co-founded Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was also the founding CEO.

Dr. Galakatos is currently a member of the Director’s Council of the Koch Institute at MIT, and the Genetics Advisory Council at Harvard Medical School.

He currently serves or has served on the board of directors of several biotechnology companies, including Affymax, Aveo, Caliper, Critical Therapeutics, Hypnion, Link Medicine, Nanostring, Portola, Syrrx, Taligen, and TransForm.

Dr. Galakatos earned his PhD in Organic Chemistry from MIT and performed his post-doctoral studies in Molecular Biology at Harvard Medical School.